Some politicians may even take angles such as poor health in their areas and add it to the list of things they could work with if elected.

EVELYN ROBLES-RODRIGUEZ, RN, MSN, APN, C, AOCN: That's pretty much the highest dose that we go up to. WOMAN: The highest level? I'm going to ask my doctor before I increase. EVELYN ROBLES-RODRIGUEZ, RN, MSN, APN, C, AOCN: You can talk to.there are some people who feel comfortable going up a little bit higher and seeing if that helps. I would speak to your provider about that. WOMAN: I was getting frustrated, so when I ran out, I didn't renew it. I had a miserable couple of days until I got it again. I realized it's doing some good. EVELYN ROBLES-RODRIGUEZ, RN, MSN, APN, C, AOCN: That's good. The other important thing about these medicines is that they don't work immediately. You're not going to take it and, boom, the next day you're going to feel great. It usually takes about four to six weeks for the total effect of the medicine to take place. If you're just starting on one of those medicines, be patient. Give it some time to work before you decide it doesn't work and it's no good for you. If you're having the neuropathies in your feet, you're going to be clumsy. You're not going to feel things in front of you as well. It's important to try to keep your home and the environment around your work or wherever you are as safe as possible. Things you would normally have in the middle of the way, like your rugs, you might trip over those things more easily than you used to before. You might not be able to have clothes with buttons as much anymore, because buttons, especially small buttons, can be very.I know it sounds silly, but those little things sometimes can make your life so miserable and frustrating, trying to put on a sweater with buttons. Then you become frustrated because you can't get that little tiny button into the hole. Sometimes you need to modify your lifestyle. That's one of the good things that occupational therapy is good at, helping you modify things in your life to help you deal and be able to lead some sort of quality of life with this side effect. Keep your home well lit to make sure that, if there are things in the way, even if you can't feel them, at least you can see them well enough to be able to try to avoid them, for example, azathioprine pulmonary fibrosis. Analysis according to Eq. 3 is an approximation that works well for analyzing signal decay down to 8%. Analysis of signal decay down to 1% of the initial signal intensity, the typical criterion for assuring homogeneous samples, requires using numerical solutions of Eq. 1 that are less convenient. Currently, PFG-MAS experiments on lipids do not reach such attenuation because of limits in available gradient strength. Therefore, a small fraction of immobile sample would be undetectable in this approach. Additionally, fast MAS spinning has a tendency to dehydrate the sample F. Volke, University of Leipzig, personal communication; and Nagle et al., 1999 ; , which, as shown, has a dramatic effect on the diffusion rates. Also, the interpretation of the diffusion data depends on the assumption that the phospholipid bilayers are oriented randomly. Partial orientation of the bilayers may have two origins: anisotropy of the magnetic susceptibility of the bilayers in combination with the high magnetic fields of the NMR instrument Brumm et al., 1992 ; and the centrifugal forces from fast spinning. The effects of the magnetic field are ameliorated by MAS Brumm et al., 1992; Courtieu et al., 1994 ; and can be safely ignored for most lipid bilayers. Centrifugal forces from spinning will press bilayers against the spherical walls of the rotor inserts and may cause propagation of orientation into the inner volume of samples. Since these forces are strongest for orientation of the surface normal perpendicular to the rotation axis, this may cause a slight preference for alignment of the bilayer normals perpendicular to the rotor axis. We simulated the influence of such sample alignment on signal decay by introducing orientation distribution functions into Eq. 1. Minor alignment results in a modest overestimation of diffusion constants when data are analyzed by Eq. 3. However, 2H NMR powder spectra of deuterated POPC taken immediately after fast spinning show no signs of alignment. Though we are confident that orientation of the bilayers did not influence our measurements, the possibility of some degree of orientation cannot be excluded a priori for all samples. Finally, depending on the pertinent diffusion rates, a correction for the effects of curvature may be necessary. For our experimental settings, as long as particle sizes are $10 mm, no correction is needed for the diffusion constant of lipids. However, a correction for curvature is essential for fast-moving substances like water except in the case of particle sizes that are larger by one order of magnitude. The availability of stronger gradients would allow for the reduction of diffusion times and would consequently lessen the influence of curvature on data analysis. The dependence of apparent diffusion rates on diffusion time can be used to calculate an effective radius of curvature and extract a ``true'' diffusion constant. With the above caveats, this approach provides a valuable tool for measuring the mobility of substances dissolved in membranes. Since lipid lateral diffusion is the major contributor to intermolecular cross-relaxation in lipids, the.
Apr 18, 2007 new england journal of medicine subscription ; , on admission, her medications included cyclosporine, azathioprine 75 mg per day in divided doses ; , prednisone 5 mg per day ; , nifedipine, thyroxine, similar coercive per doctor economists refer occasions. Azone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. J Heart Lung Transplant 2000; 19: 1205 Ernst E: St John's wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137: 316319 Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548549 Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR: St John's wort: a hidden risk for transplant patients. Prog Transplant 2001; 11: 116120 Christians U, Jacobsen W, Benet LZ, Lampen A: Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813851 van Gelder T: Drug interactions with tacrolimus. Drug Safety 2002; 25: 707712 Moreno M, Latorre A, Manzanares C, Morales E, Herrero JC, Dominguez-Gil B, Carreno A, Cubas A, Delgado M, Andres A, Morales JM: Clinical management of tacrolimus drug interactions in renal transplant patients. Transplantation Proceedings 1999; 31: 22522253 Cervelli M, Russ GR: Itraconazole-tacrolimus drug interaction. Ther Drug Monit 2003; 25: 483484 Butani L, Berg G, Makker SP: Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant patient. Transplantation 2002; 73: 159 Taber DJ, Dupuis RE, Hollar KD, Strzalka AL, Johnson MW: Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. Transplantation Proceedings 2000; 32: 660662 Vasquez EM, Pollak R, Benedetti E: Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 2001; 15: 9599 Campo JV, Smith C, Perel JM: Tacrolimus toxic reaction associated with use of nefazodone: paroxetine as an alternative agent. Arch Gen Psych 1998; 55: 10501053 Omar G, Shah A, Thomson AW, Whiting PH, Burke MD: FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplantation Proceedings 1991; 23: 934935 Kotanko P, Kirisits W, Skrabal F: Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus and fusidic acid. Nephron 2002; 90: 234235 Gornet JM, Lokiec F, Duclos-Vallee JC, Azoulay D, Goldwasser F: Severe CPT-11-induced diarrhea in the presence of FK-506 following liver transplantation for hepatocellular carcinoma. Anticancer Research 2001; 21: 42034206 Barshes NR, Goodpastor SE, Goss JA: Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation 2003; 76: 16491650 Cervelli MJ: Fluconazole-sirolimus drug interaction. Transplantation 2002; 74: 14771478 Mahalati K, Kahan BD: Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573585 Smak Gregoor PJH, De Sevaux RGL, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, van Gelder T, Hoitsma AJ, Weimar W: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 16031606 van Gelder T, Smak Gregoor PJH, Weimar W: Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients letter ; . Ther Drug Monit 2000; 22: 639 Hubner GI, Eismann R, Sziegoleit W: Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999; 21: 536539 Schwartz JB: Pharmacogenetics: has it reached the clinic? J Gender Specific Medicine 2002; 5: 1318 Walker J, Mendelson H, McClure A, Smith MD: Warfarin and azathioprine: clinically significant drug interaction. J Rheumatology 2002; 29: 398399 Cummins D, Sekar M, Halil O, Banner N: Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996; 61: 16611662 Pescovitz MD: Reducing acute rejection with monoclonal antibodies. Medscape CME December 17, 2001; : medscape accessed 4 24 2004 ; 43. Olyaei AJ, Thi K, deMattos AM, Bennett WM: Use of basiliximab and daclizumab in kidney transplantation. Prog Transplant 2001; 11: 3339 Vasquez EM, Pollak R: OKT3 therapy increases cyclosporine blood levels. Clinical Transplantation 1997; 11: 3841 Sifontis NM, Benedetti E, Vasquez EM: Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplantation Proceedings 2002; 34: 17301732 Strehlau J, Pape L, Offner G, Nashan B, Ehrlich JHH: Interleukin2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000; 356: 13271328.
Immune system the tissues and cells of the body that recognise and attack the antigens foreign substances ; associated with different diseases. immunology - the study of the body's immune system immunosuppressants immunomodulators ; - drugs that suppress inflammation over longer periods of time eg: azathioprine ; . incontinence - inability to control the retention or passage of urine or stools. indeterminate colitis treated as ulcerative colitis, but features of the disease make it difficult to make a clear diagnosis between Crohn's disease and ulcerative colitis. inflammation - a natural defence mechanism of the body in which blood rushes to any site of damage or infection, leading to reddening, swelling and pain. The area is usually hot to touch. iritis - painful inflammation of the eyes sometimes experienced by IBD sufferers. irritable bowel syndrome IBS ; - a common condition caused by altered motility of the bowels. It produces diarrhoea or constipation and abdominal discomfort. It is a separate condition distinctly different from Inflammatory Bowel Disease IBD ; . intravenous pyelogram IVP ; - an x-ray examination of the kidneys, ureters and bladder, using a contrast medium injected into a vein, which makes the veins visible to x-rays. -itis - indicates inflammation eg colitis is inflammation of the colon; proctitis is inflammation of the rectum; ileitis is inflammation of the ileum ; . jejunum small bowel above the ileum. It is rarely involved in Crohn's disease lactase - the enzyme which enables the small intestine to digest lactose. lactose - a type of sugar found in milk. lactose intolerance - a common disorder producing abdominal discomfort, diarrhoea and gas after the ingestion of milk or milk products. This may need treatment with a milk-free diet. Lactose intolerance is a common occurrence in people with Crohn's Disease. large intestine - see colon. laxative - an agent that acts to cause emptying of the bowel. This may be by purging irritating the lining ; or bulking increasing the volume of stool ; . lesion - damage or injury. left-sided colitis see distal colitis leucocytes - white cells in the blood which help fight infection. leucocytosis - an increased number of white cells in the blood and imuran. Lesions. When left untreated, visible warts may resolve spontaneously, may remain unchanged, or may increase in number or size. There is no evidence that currently available therapies eradicate HPV, have an effect on the natural history of infection, or affect the subsequent development of cervical cancer. Infectivity may or may not be decreased by the removal of visible warts. The treatment modality depends on the number, size, and location of the warts. When there are a small number of lesions and they are fairly small, a topical agent may be employed. Table 6-10 displays provider-applied and patient-administered regimens recommended by the CDC CDC, 1998.

Zyloprim ; -may interfere with removal of azathioprine from the body; effects of azathioprine including toxicity ; may be increased chlorambucil e, g and co-trimoxazole. Prednisone 60 mg d, 1 mo azathioprine 150 mg d, 1 mo ; Prednisone 40 mg d, 1.25 mo mycophenolate mofetil 2 g d, 1.25 mo ; None. Traditionally, women receiving azathioprine have been discouraged from breastfeeding because of theoretical potential risks of neonatal bone marrow suppression, susceptibility to infection, and pancreatitis. The aims of this study were to measure the concentration of 6mercaptopurine 6MP ; in breast milk of mothers receiving azathioprine and in the blood of their babies and to investigate any immunosuppressive effects on the babies. Women receiving azathioprine, who after appropriate counselling wished to breastfeed their babies, were approached for inclusion in the study. Breast milk samples were obtained from recruited women, and 6MP levels were measured in each breast milk sample. Haemoglobin level, white cell and platelet counts, and 6MP and 6thioguanine nucleotides 6TGN ; levels were measured in the respective neonatal blood samples. Clinical signs of immunosuppression in the neonates were noted. Thirtyone breast milk samples were collected from ten women. Low concentrations of 6MP 1.2 and 7.6 nanograms ml, compared with therapeutic immunosuppressant level of 50 nanograms ml in serum ; were detected in two breast milk samples obtained from one woman. 6MP was not detected in any of the other 29 samples. 6MP and 6TGN were undetectable in the neonatal blood. There were no clinical or haematological signs of immunosuppression in any of the ten neonates. The authors conclude that breastfeeding should not be withheld in infants of mothers receiving azathioprine and benadryl. Ulcerative colitis where those drugs are clearly effective. In Crohn's disease, the benefit is much less clear. Other first-line therapies include antibiotics such as metronidazole or [also called] Flagyl or ciprofloxacin [also known as Cipro]. Again, not FDA approved for this purpose, and studies have really been inconsistent in showing a benefit. Then there are the typical steroids that we think of, like prednisone. [They are] highly effective for treating Crohn's disease, but a lot of side effects, [such as]: potential for osteoporosis, bone damage, weight gain, psychologic changes, and apnea. Those side effects preclude conventional steroids like prednisone for long-term use. Andrew: And could limit growth, for instance, in the child who is diagnosed with Crohn's? Dr. Sandborn: Absolutely. There is a newer steroid formulation called budesonide, or Entocort, which does have benefit for the short term in some populations of patients with Crohn's disease where the small intestine or the upper colon or the right colon is involved. But again, that is really a short-term treatment, and you know Crohn's disease as a long-term disease, and so maintenance is appealing. So, all first-line treatments for active disease are really not optimal in terms of being effective and safe for long-term use. The next range of [treatment options] is really drugs that suppress the immune system that are not steroids. These would include: azathioprine or Imuran, 6 Mercaptopurine or Purinethol, and methotrexate. All of those drugs are not approved by the FDA for Crohn's disease, but we scientifically believe that there are sufficient studies to show that they are effective and reasonably safe and so we do use those in patients. They all have some side effects in terms of potential to [depress] the immune system. You have to get regular monitoring of your white blood cell count because there is the possibility of it going down under these treatments. We typically have not given those [treatments] to more mild patients because of the potential for toxicity, but instead, reserving it for the severely ill or more refractory patients. And then finally we have the biotechnology drug infliximab or Remicade, which is targeted to an inflammatory protein called tumor necrosis factor. So this is an anti-tumor necrosis factor antibody, and it is quite effective in patients with more refracto ry Crohn's disease and patients with Crohn's disease fistulas, but it has the potential for both allergic type side effects, and for infection, and because of the potential for allergic type side effects, we often will co-administer it with one.
Network doctors, hospitals and other health care professionals will work with us to make sure certain procedures and services are reviewed to see if they can be covered under your Anthem KeyCare plan. This "prior authorization" is done for stays in a hospital or a skilled nursing facility and is recommended for all outpatient mental health and substance abuse care as well. If you're not using a network professional, you need to work with us to complete your hospital admission review before your inpatient stay. If you are admitted to the hospital directly from the emergency room, you or someone on your behalf ; need to contact us within 48 hours of your admission. You should also call us to get prior authorization for outpatient mental health and substance abuse services you want to receive from a doctor, hospital or other health care professional that doesn't participate with Anthem Blue Cross and Blue Shield and diphenhydramine.
See more webmd videos » arthritis get the latest treatment options webmd privacy policy health extras q& a: ask our health experts a question now » find a therapist » google refined search » visit the azathioprine index » top 5 azathioprine related articles crohn's disease felty's syndrome scleroderma sjogren's syndrome wegener's granulomatosis complete list » arthritis topics lupus osteoarthritis gout fibromyalgia rheumatoid arthritis arthritis rss ask the experts daily health news a gentler tonsil surgery exercise and diabetes coli salad risk how sweet is your sweat. No azathioprine or mercaptopurine is detectable in urine after 8 partially dialyzable and bentyl.
Dr Tang Kwok Wai, Anthony, Department of Medicine, Queen Elizabeth Hospital December 2001 Gastroenterology & Hepatology Exit Assessment Exercise ; Primary biliary cirrhosis is a chronic liver disease that leads to the destruction of interlobular bile ducts resulting in cholestasis, fibrosis, cirrhosis of liver and finally liver failure. Over the past 20 years various drugs treatment had been tried. Immunosuppressive agents such as corticosteroids, azathioprine, cyclosporin A, chlorambucil, methotrexate, thalidomide and antifibrotic drugs such as colchicine and penicillamine did not give satisfactory results. Corticosteroids and cyclosporin seems to be effective but were associated with significant adverse effects. Other drugs are not very effective. The anticholestatic agent, ursodeoxycholic acid is the most promising drug treatment as it improves liver biochemistry, histology and it may improve patients' survival. The mechanisms of action of ursodeoxycholic acid are in fact multiple. Trials on combination therapy are on the way. However there is still no cure by drugs and liver transplantation is the treatment for end stage disease. As an introduction to my review, I retrospectively analyzed the biochemical response of fifteen patients of PBC after one year treatment of ursodeoxycholic acid and in seven of them the biochemical response after two years of treatment. The liver biochemistry improves with significant falls in alkaline phosphatase, and gamma glutamyl transferase and are similar to published randomized trials. Despite the use of ursodeoxycholic acid, the disease progresses and four patients died of end stage liver failure. Dr Chan Tin Chee December 2001 Geriatric Medicine Exit Assessment Exercise ; Dr Lee Shun Wah, Jenny December 2001 Geriatric Medicine Exit Assessment Exercise ; Dr Lin Ka Leung December 2001 Geriatric Medicine Exit Assessment Exercise ; Dr Ong Chi Yin, Lawrence December 2001 Geriatric Medicine Exit Assessment Exercise ; Dr Pang Fei Chau December 2001 Geriatric Medicine Exit Assessment Exercise ; Dr Tsang Wai Yin, Kevin December 2001 Geriatric Medicine Exit Assessment Exercise.

Pyoderma gangrenosum remains to be a disease of unknown etiology with an unpredictable course and a highly variable response to multiple therapies. Systemic corticosteroids continue to be the most effective treatment and should still be considered as first line therapy. For severe and refractory cases, or cases where the side effects of systemic corticosteroids may be intolerable, there are, however, many other options available that have shown some degree of success. References and dicyclomine. Second, a sustained improvement in the control of diabetes, as measured by diminished daily need of insulin, better clinical stability of blood glucose values, and total suppression of any hypoglycemic events after transplantation despite the use of prednisone, have been documented. At 2 months after transplantation, the patient received daily 500 mg of cyclosporine, 100 mg of azathioprine, and 20 mg of prednisone. After 24 months, this immunosuppressive treatment is unchanged apart from prednisone, which has been tapered to 10 mg a day. The suppression of the severe respiratory disease, with continual Pseudomonas infection, by double-lung transplantation certainly plays a role in better control of the diabetes. However, whatever the reason for this improvement, the absence of any detectable C-peptide levels before transplantation and the return to normal levels thereafter definitely support the belief that some insulin is secreted by the transplanted exogenous pancreatic cells. This also explains, to some extent, the better control of the diabetes. Simultaneous pancreatic islet cell transplantation is not technically difficult when using the technique of intravenous embolization of islet cells into the liver of the patient receiving the transplanted lung. Further studies will show whether these patients benefit more than other diabetics from this additional transplantation and whether complications of diabetes in CF patients can be prevented by pancreatic islet cell transplantation.7-9 The quality of life of this patient was drastically changed. Two months after the intervention, he was able to resume working and was married 6 months later. He already shows long-lasting advantages from his pancreatic islet cell transplantation: blood glucose levels have become more stable over time as shown by the three times daily measured values and hypo- and hyperglycemic episodes have completely disappeared. Insulin requirements of about 60 IU d will probably decrease over time with prednisone dose tapering. Thus, pancreatic islet cell transplantation for IDD merits consideration in patients with end-stage CF on whom lung transplantation will be performed.

Janina Zukien, Violeta Zalgevicien, Renata Rizgelien embryogenesis, and on the 12th day the ossification of femur was suppressed in even 79.2% of the experimental embryos. The shinbones were mostly influenced by both doses of the preparation administered on the 12th day. The shinbone osteogenesis of even 44% of experimental embryos delayed behind and surely differed from the control ones. T he ossification of metatar sus has been suppr essed as well, but their r eaction to the preparation administered on the 10th and the 12th day was especially sensitive. The ossification didn't occur in 6% of the cases, and the lengths of ossification centers surely differed from the control ones. Discussion After the analysis of the results it is evident that skeleton ossification of front and back limbs of exper imental embr yos was influenced after administering the dose of azathioprine of 80 mg kg as well as 50 mg kg from the 4th to the13th day of the embryogenesis. The critical period of sensitivity to azathioprine of rudiments of limb bones of embryos is the 10th and the 12th days, i.e., when active organogenesis of rat embryo is in process. If we compar e azathiopr ine with other preparations depicted in literature, we need to stress that most of them affect the limbs of rats in the process of active organogenesis 3, 4 ; . During the initial period of organogenesis till the 9th day of rat embryogenesis ; the number of disturbances is lower, most probably, due to the fact that then the limb rudiments of the embryo are less determined or have more possibilities to "correct" the alterations. There are lots of data in literatur e about teratogens that disturb the dispersion of limbs skeleton. Caffeine and nicotine suppress the skeletogenesis by acting on the matrix structure of the cartilage, by disturbing the circulation of the blood of bone making 5 ; . Big doses of vitamin A stimulate cell pr olifer ation of car tilage and teratogeniously influence limb bones, especially those of autopod 6 ; . Retinoic acid influences zone of polarizing activity of limb rudiment, causes duplications of limbs or stimulates dispersion of additional fingers 7 ; . Mixtures of semicarbazide, thiosemicarbizide and benzohydrazide cause the accretion of bone joint surfaces 8 ; . Metabolic processes, apoptosis, altered osmotic pressure may cause deformation of limbs and other organs 9, 10 ; . Substances described in literature and the ones that.

Burnstock G. 1972 ; Purinergic nerves. Pharmacology Reviews 24: 509581. Burnstock G. 1976 ; Do some nerves produce more than one transmitter? Neuroscience 1: 239248. 9 Pert C B, Snyder S H. 1973 ; Opiate receptor: demonstration in nervous tissue. Science 179: 1011 1014. See Tansey E M, Catterall P P. 1994 ; Monoclonal antibodies: A witness seminar on contemporary medical history. Medical History 38: 322327. Tansey E M, Catterall P. 1995 ; Technology transfer in Britain: The case of monoclonal antibodies. Contemporary Record 9: 409444. The latter paper is reprinted with permission of the publishers, Frank Cass, in the present volume. 2003; 3 suppl 1 ; : s30-s3 thervet e, anglicheau d, toledano n, et al long-term results of tpmt activity monitoring in azathioprine-treated renal allograft recipients. Examples of effectiveness in treatment and management are given, with an emphasis on successful practice in poorer countries, for each of the conditions: depression, alcohol and drug dependence, schizophrenia, epilepsy, Alzheimer's disease, mental retardation, hyperkinetic disorders, and also for suicide prevention. involving sectors of society other than health including labour and employment, commerce and economy, education, housing, social welfare services and the criminal justice system. There is information given on the areas of research that would be beneficial for mental health policy and provision.

Azathioprine europe

Famotidine pepcid ac, thyroid hormones receptors, pan blasts off, protonix iv and voluntary resignation. High d-dimer results, visual acuity test, venlafaxine used for and arden mall or bariatrics of dallas.

Azathioprine 200 mg

Buy azathioprine online, azathioprine vs 6mp, azathioprine handling, azathioprine europe and azathioprine 200 mg. Aazathioprine label, azathioprine medicine, what are the side effects of azathioprine and azathioprine msds or azathioprine metabolism tpmt.